Jadeite

CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan

Retrieved on: 
Tuesday, October 12, 2021

Jadeite will be responsible for clinical development, regulatory approval and commercialization of odevixibat in Japan, where there is significant market opportunity.

Key Points: 
  • Jadeite will be responsible for clinical development, regulatory approval and commercialization of odevixibat in Japan, where there is significant market opportunity.
  • "This agreement reinforces Jadeite's commitment and vision to develop highly differentiated and innovative medicines to improve the health and quality of life of patients in Japan."
  • "The agreement allows for success of both companies, and we look forward to further collaboration with Jadeite."
  • "CBC remains steadfast in our commitment to widening access to medical care globally, and Jadeite is our cornerstone in Japan.